Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis

We read the paper by Davies Forsman et al. [1] and could not agree more with their findings. The authors report that in the studied geographical area and clinical population, the dose of levofloxacin and moxifloxacin should be increased to achieve the optimal exposure target in order to effectively treat multidrug-resistant tuberculosis, and suggested therapeutic drug monitoring (TDM) to avert any adverse event [1, 2]. The target drug exposure and dose in the study were selected based on the evidence collected using pharmacokinetic/pharmacodynamic studies in both pre-clinical models and in the clinic [3].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Correspondence Source Type: research